ArticleScience advances2023
TOX2 coordinates with TET2 to positively regulate central memory differentiation in human CAR T cells.
Open access · goldAbstract read
In one paragraph
Article in Science advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 26 citations in OpenAlex.
- The long noncoding RNA Peanut (Gm11454) biases progenitors towards neurogenesis and rod photoreceptor differentiation during postnatal retinal development.Developmental biology · 2026Article
- Linperlisib enhances MUC1-Tn CAR T cell efficacy by inhibiting EGR1/DUSP2 axis to prevent CAR T cell exhaustion.Leukemia · 2026Article
- Distinct roles of STAT3 and STAT5 in CAR T cell therapy.Molecular therapy. Oncology · 2026Article
- Memory programming and new manufacturing paradigms in CAR-T cell therapy.Cancer gene therapy · 2026Review
- The Potential of the Gut Microbiota and Butyrate to Enhance CAR T-cell Therapy in Non-Hodgkin Lymphoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Next-generation CAR-T cells design: leveraging tumor features for enhanced efficacy.Molecular cancer · 2025Review
- CD2 costimulation strength: A key regulator of T cell function and anti-tumor immunity that is epigenetically regulated.iScience · 2025Article
- Pomalidomide enhances CAR-T cell therapeutic efficacy and remodels immune microenvironment in lymphoid malignancies.Cancer immunology, immunotherapy : CII · 2025Article
- The long noncoding RNAbioRxiv : the preprint server for biology · 2025Article
- Scalable transcription factor mapping uncovers the regulatory dynamics of natural and synthetic transcription factors in human T cell states.bioRxiv : the preprint server for biology · 2025Article
- Challenges and perspectives of CAR-T cell therapy in solid tumours: insights from gastric cancer.British journal of cancer · 2025Review
- CD8Science advances · 2025Article
- Enhancing the potency of CAR-T cells against solid tumors through transcription factor engineering.JCI insight · 2025Review
- The TET-TDG axis in T cells and biological processes.International immunology · 2025Review
- The epigenetic hallmarks of immune cells in cancer.Molecular cancer · 2025Review
- TET2 regulates early and late transitions in exhausted CD8Science advances · 2024Article
- TET2 mutation in acute myeloid leukemia: biology, clinical significance, and therapeutic insights.Clinical epigenetics · 2024Review
- TOX2 nuclear-cytosol translocation is linked to leukemogenesis of acute T-cell leukemia by repressing TIM3 transcription.Cell death and differentiation · 2024Article
- Unlocking T cell exhaustion: Insights and implications for CAR-T cell therapy.Acta pharmaceutica Sinica. B · 2024Review
- Decoding and overcoming T cell exhaustion: Epigenetic and transcriptional dynamics in CAR-T cells against solid tumors.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Sierra M CollinsDepartment of Cell and Developmental Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0002-8174-9659
Katherine A AlexanderDepartment of Cell and Developmental Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0001-6418-6615
Stefan LundhDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, PA 19104, USA.ORCID 0000-0003-2527-3497
Alexander J DimitriCenter for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0002-7337-3196
Zhen ZhangDepartment of Cell and Developmental Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0001-9074-2689
Charly R GoodDepartment of Cell and Developmental Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Joseph A FraiettaDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, PA 19104, USA.ORCID 0000-0001-7900-8993
Shelley L BergerDepartment of Cell and Developmental Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0001-5398-4400
University of Pennsylvania · US
Funding
UNIVERSITY OF PENNSYLVANIA CAN CTR SUPPORT GRANTP30CA016520 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Robert H. Vonderheide · 1985 to 2026
$222.3MProject 3: Combinatorial and gene-editing approaches to enhance the efficacy of CAR T cell therapy of multiple myeloma.P01CA214278 · NCI · UNIVERSITY OF PENNSYLVANIA · PI CARL H. JUNE · 2017 to 2026
$26.8MRole of PCAF/GCN5 Acetylation on p53 TransactivationR01CA078831 · NCI · WISTAR INSTITUTE · PI BERGER, SHELLEY L · 1999 to 2022
$7.8MProject 3U54CA244711 · NCI · UNIVERSITY OF PENNSYLVANIA · PI JUNE, CARL H. · 2019 to 2022
$7.1MInteraction between nuclear epigenetic and metabolic pathways in cancerR35CA263922 · NCI · UNIVERSITY OF PENNSYLVANIA · PI SHELLEY L BERGER · 2022 to 2026
$4.8MDeterminants of CD8+ T Cell Aging and Reduced Function in B Cell CancerU01AG066100 · NIA · UNIVERSITY OF PENNSYLVANIA · PI JUNE, CARL H. · 2019 to 2020
$243kModulation of wild type and mutant p53 by HMGA1F32CA221010 · NCI · UNIVERSITY OF PENNSYLVANIA · PI ALEXANDER, KATHERINE ANN · 2018 to 2020
$188kInvestigating TOX2 as a novel regulator of T cell memory differentiationF31CA239428 · NCI · UNIVERSITY OF PENNSYLVANIA · PI MCDONALD, SIERRA · 2019 to 2020
$91kNovel Roles of p53 Post Translational Modifications in CancerF32CA232466 · NCI · UNIVERSITY OF PENNSYLVANIA · PI GOOD, CHARLY RYAN · 2019 to 2019
$53kNCI NIH HHS F31 CA239428NCI NIH HHS F32 CA221010NCI NIH HHS F32 CA232466NCI NIH HHS P01 CA214278NCI NIH HHS P30 CA016520NCI NIH HHS R01 CA078831NCI NIH HHS R35 CA263922NCI NIH HHS U54 CA244711NIA NIH HHS U01 AG066100
Abstract
Chimeric antigen receptor (CAR) T cell therapy is used in treating human hematological malignancies, but its efficacy is limited by T cell exhaustion (T
Indexed as
DioxygenasesNeoplasmsCell DifferentiationDNA-Binding ProteinsHMGB ProteinsHumansImmunotherapy, AdoptiveT-LymphocytesDioxygenasesDNA-Binding ProteinsHMGB ProteinsTET2 protein, humanTox2 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.